ROS1 and non-small cell lung carcinoma: The clinical efficacy of lorlatinib against ROS1–NSCLC was investigated in the multicenter NCT01970865 study, which included 69 ROS1-positive advanced NSCLC patients with no restrictions regarding CNS metastases [25,37].